NR3C2 and hydrops fetalis: HF guidelines recommend the use of themaximum tolerated target dose of angiotensin-converting enzyme inhibitors (ACEIs)or angiotensin-receptor blockers (ARBs), beta blockers (BBs), mineralocorticoidreceptor antagonists (MRAs), ivabradine, and angiotensin-receptor-neprilysininhibitors (ARNIs) to reduce mortality and/or readmission rates due to HF [5, 6].Several studies have also shown that the use of these drugs can reduce morbidityand mortality in patients with HF [7, 8].